作者: galley 時(shí)間: 2025-3-21 22:13
s.Written by experts in their fields.Includes supplementary As there are a number of nuances in terms of how to manage mutation carriers (both with and without a concomitant diagnosis of breast cancer), this text provides a comprehensive, state-of-the art review of this field. It represents a valuab作者: Forsake 時(shí)間: 2025-3-22 01:58
Risk Assessment for Breast Cancer,ic testing; and most important, ensure that the patient follows through. With each of these steps, a certain proportion of patients is lost. Mary-Claire King, the human geneticist who discovered the . mutation, once stated that “to identify a woman as a carrier only after she develops cancer is a failure of cancer prevention.” We can do better.作者: aneurysm 時(shí)間: 2025-3-22 08:31 作者: mortgage 時(shí)間: 2025-3-22 11:47 作者: 制定法律 時(shí)間: 2025-3-22 13:24 作者: FLEET 時(shí)間: 2025-3-22 18:12
Risk Assessment for Breast Cancer,fected . mutation carriers before they develop breast cancer can reduce their risk and increase survival through increased intensity and frequency of screening, prophylactic surgery, and use of chemopreventive agents. Although the tools for genetic testing have been available for the past 20?years, 作者: Indolent 時(shí)間: 2025-3-22 21:45
Genetic Evaluation for Women at Increased Risk,family history of cancer that may be associated with a hereditary cancer predisposition. The collection of an accurate, cancer-focused family history is the foundation of this risk assessment. Professional organizations have created guidelines outlining when patients should be referred to a provider作者: 吹牛大王 時(shí)間: 2025-3-23 02:23
Imaging Screening and Surveillance,sitivity of screening MRI in this population is 90–95%, more than twice that of mammography, with a specificity of over 90% after the first round of screening. Ten-year breast cancer-free survival, though likely somewhat lower than that with risk-reducing mastectomy, is at least 90%. The incremental作者: sigmoid-colon 時(shí)間: 2025-3-23 08:25
Risk-Reducing Surgery for , Genetic Mutation Carriers,y has been shown to reduce the risk of breast cancer by 90% or more among high-risk women including . mutation carriers. The decision to undergo prophylactic surgery is a choice that patients make, in conjunction with their multidisciplinary healthcare team which often includes genetic counselors, s作者: foppish 時(shí)間: 2025-3-23 10:59 作者: Asseverate 時(shí)間: 2025-3-23 16:33 作者: 時(shí)代錯(cuò)誤 時(shí)間: 2025-3-23 19:10
Surgical Management of Breast Cancer in , Mutation Carriers,es. This recognition has led to many questions regarding the optimal surgical management for those considered to be high risk. There is no consensus on what constitutes the best surgical management of primary breast cancer in. mutation carriers. Several aspects need be considered during the surgical作者: grenade 時(shí)間: 2025-3-24 00:03 作者: 外觀 時(shí)間: 2025-3-24 05:42
Radiation Oncology Considerations in the Management of Mutation Carriers with Breast Cancer,cer with TNBC, present guidelines for genetic screening suggest that all TNBC patients younger than 60?years, irrespective of family history, should be considered for genetic testing. Though genetic status will ultimately guide in the local treatment management decisions, the long-term implications 作者: minion 時(shí)間: 2025-3-24 08:14
Fertility Preservation in , Carriers: Special Considerations,ntries, women under the age of 45 are more likely to die of breast cancer than of any other disease or injury [.]. Women with hereditary breast and ovarian cancer syndromes, including carriers of deleterious mutations in the . or . genes, not only are at approximately fivefold increased risk of brea作者: URN 時(shí)間: 2025-3-24 12:20
Management of Male , Mutation Carriers,t cancer and 5–10% are associated with germline cancer susceptibility gene mutations. Unfortunately, with such small numbers, the research opportunities and data available on the biology, diagnosis, and management of male breast cancer have been limited. The management of male breast cancer, therefo作者: 生銹 時(shí)間: 2025-3-24 17:20
Psychosocial, Ethical, and Legal Implications for Mutation Carriers,th hereditary breast and ovarian cancer (HBOC) syndrome due to inherited . and . gene mutations. While cancer risk may be mitigated by enhanced surveillance, chemoprevention, and/or risk-reducing surgery, careful attention must be paid to psychosocial aspects of genetic testing, risk communication w作者: stress-response 時(shí)間: 2025-3-24 20:39
Dario R. Roque,Don S. Dizond Marktkommunikanten zugleich auch ihre jeweiligen Kommunikationspartner im Auge zu behalten, ist für die systematische Durchleuchtung der marktsemiotischen Zusammenh?nge wichtig genug, in einem gesonderten Abschnitt über die Schaltungen der Marktkommunikation genauer behandelt zu werden. Als Schalt作者: Esophagus 時(shí)間: 2025-3-25 02:36 作者: emulsify 時(shí)間: 2025-3-25 05:11 作者: collagenase 時(shí)間: 2025-3-25 09:13 作者: 完成 時(shí)間: 2025-3-25 14:39 作者: 要求比…更好 時(shí)間: 2025-3-25 19:45 作者: condemn 時(shí)間: 2025-3-25 19:59 作者: Acetabulum 時(shí)間: 2025-3-26 04:11
Jacquelyn M. Powers,Jessica M. Long,Willonie Mendoncationieren. Die Website ist meistens die erste Kontaktm?glichkeit, die Besucher (Konsumenten) mit dem betreffenden Unternehmen haben und sie fungiert darum auch als Visitenkarte für die Organisation. Dies gilt sicherlich auch für eine medizinische Website, welche eine wichtige Informationsquelle über作者: Inferior 時(shí)間: 2025-3-26 07:46 作者: Feckless 時(shí)間: 2025-3-26 08:56 作者: 平庸的人或物 時(shí)間: 2025-3-26 14:50 作者: 爭(zhēng)論 時(shí)間: 2025-3-26 18:15 作者: 馬具 時(shí)間: 2025-3-27 01:03
Cristina O’Donoghue,Sonia Orcutt,Tuya Pal,Christine Laronga作者: 聽覺(jué) 時(shí)間: 2025-3-27 03:47
Genetic Evaluation for Women at Increased Risk, includes intake, risk assessment, pretest counseling and informed consent, and result disclosure and interpretation. Though the focus of this volume is the management of individuals with . mutations, any current discussion of hereditary breast and ovarian cancer would not be complete without mentio作者: 允許 時(shí)間: 2025-3-27 07:10
Imaging Screening and Surveillance, psychological consequences. There is no role for screening with any imaging modality in asymptomatic women who have undergone risk-reducing mastectomy. For . mutation carriers who have not undergone risk-reducing salpingo-oophorectomy by the recommended age, there is no evidence to date that ovaria作者: Trigger-Point 時(shí)間: 2025-3-27 09:40
Prophylactic Oophorectomy for Patients with Germline , Mutations, The procedure can be performed laparoscopically and can be combined with a hysterectomy in some patients including women with Lynch syndrome and those who will take tamoxifen or hormone replacement therapy following their rrBSO. However, despite the tremendous benefits derived from rrBSO in this pa作者: 施舍 時(shí)間: 2025-3-27 16:49 作者: ALE 時(shí)間: 2025-3-27 21:02 作者: amplitude 時(shí)間: 2025-3-27 22:07
Fertility Preservation in , Carriers: Special Considerations,g. This should be considered for both previvors (patients who are .?+?but have not developed disease) and .?+?survivors (patients who have developed disease in the setting of a hereditary predisposition). While male . carriers are at increased risk of developing malignancies, most present later in l作者: 指令 時(shí)間: 2025-3-28 02:32 作者: 織布機(jī) 時(shí)間: 2025-3-28 10:02 作者: helper-T-cells 時(shí)間: 2025-3-28 11:35 作者: Creditee 時(shí)間: 2025-3-28 15:53
Dario R. Roque,Don S. DizonHandelsbetrieb, Marktpublizist oder Konsument — die jeweiligen Anfangs-, Zwischen- und Endglieder einer marktsemiotischen Schaltung besetzt sind, und da? eine Verbindungslinie zwischen zweien dieser Symbole auf die Existenz zumindest eines Kommunikationskanals zwischen den durch diese repr?sentierte作者: 我邪惡 時(shí)間: 2025-3-28 22:40 作者: 粗糙 時(shí)間: 2025-3-29 02:52
Patricia A. Cronin,Hiram S. Cody III wie dies zum Verst?ndnis der L?sungen und der technologischen Potentiale erforderlich ist, k?nnte mit dem Verh?ltnis von Telefonmarketing und der technischen Realisierung des dazu erforderli- chen Telefonnetzes verglichen werden. Da? der Autor auch über das erforderliche technische Wissen verfügt, hat er meh978-3-8244-6908-6978-3-322-92338-7作者: 亞麻制品 時(shí)間: 2025-3-29 05:49 作者: Optometrist 時(shí)間: 2025-3-29 07:44
Meena S. Morang der Websites von pharmazeutischen Firmen zu geben, die es erm?glichen, Websites als Marketingkommunikationsinstrument wirksamer einzusetzen. Obwohl das Untersuchungsspektrum des vorliegenden Beitrags vom Ansatz her landeskulturell übergreifend auf die branchenspezifische Website-Kommunikation phar作者: Limited 時(shí)間: 2025-3-29 12:12 作者: homocysteine 時(shí)間: 2025-3-29 16:28
Donna-Marie Manasseh,Ryland J. Gore,Patrick I. Borgeng der Websites von pharmazeutischen Firmen zu geben, die es erm?glichen, Websites als Marketingkommunikationsinstrument wirksamer einzusetzen. Obwohl das Untersuchungsspektrum des vorliegenden Beitrags vom Ansatz her landeskulturell übergreifend auf die branchenspezifische Website-Kommunikation phar作者: BIDE 時(shí)間: 2025-3-29 23:44
Jacquelyn M. Powers,Jessica M. Long,Willonie Mendoncag der Websites von pharmazeutischen Firmen zu geben, die es erm?glichen, Websites als Marketingkommunikationsinstrument wirksamer einzusetzen. Obwohl das Untersuchungsspektrum des vorliegenden Beitrags vom Ansatz her landeskulturell übergreifend auf die branchenspezifische Website-Kommunikation phar作者: aptitude 時(shí)間: 2025-3-30 02:31
g der Websites von pharmazeutischen Firmen zu geben, die es erm?glichen, Websites als Marketingkommunikationsinstrument wirksamer einzusetzen. Obwohl das Untersuchungsspektrum des vorliegenden Beitrags vom Ansatz her landeskulturell übergreifend auf die branchenspezifische Website-Kommunikation phar
